Company Overview and News

30
TransEnterix Stock Rose 5.6% on Friday and Early on June 4

2018-06-04 marketrealist
TransEnterix (TRXC) is a US-based medical device company that focuses on digitizing the interfaces between the surgeon and the patient. The stock price increased ~5.6% and closed at $3.75 on June 1. The stock rose ~3.2% to $3.87 in the pre-market session on June 4.
SGRY FATE UTMD SPSM

14
8
Surgery Partners, Inc. to Present at Upcoming Investor Conferences

2018-05-11 globenewswire
NASHVILLE, Tenn., May 11, 2018 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners”), a leading healthcare services company, today announced that management will present at the following conferences:
SGRY

8
Surgery Partners' (SGRY) CEO Wayne DeVeydt on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Greetings, and welcome to the Surgery Partners Inc. First Quarter 2018 Earnings Conference Call. At this time, all participants will be in a listen only mode. A question and answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
SGRY

8
Surgery Partners, Inc. Announces First Quarter 2018 Results

2018-05-09 globenewswire
BRENTWOOD, Tenn., May 09, 2018 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading provider of surgical services, today announced results for the first quarter ended March 31, 2018.
SGRY

101
Xerium Technologies: The Cause For One's Case Of Delirium Or A Nice Improvement In Their Asset's Valuation

2018-05-01 seekingalpha
I will discuss the issues that have placed Xerium in their current situation and what the future might hold.
MNKD XRM NKTR SGRY LNDC BLBD BLMN HW VASC KINS JWN SBUX BRSS

8
SGRY / Surgery Partners, Inc. DEF 14A

2018-04-19 sec.gov
Document
SGRY

30
These 5 Stocks Could Be in Big Trouble If Interest Rates Go Higher

2018-04-07 247wallst
The market volatility has been elevated so far in 2018, and if the current geopolitical and financial concerns stay in place, even temporarily, you can expect things to stay that way. While trade has been among the issues whipsawing the market, rising interest rates have been a major concern as well. If rates continue higher, companies with floating rate debt could face some major issues.
SGRY MD ACHC BIOS

10
8
BRIEF-Surgery Partners Announces Appointment of Thomas Cowhey As CFO

2018-03-12 reuters
* SURGERY PARTNERS INC - COWHEY JOINS SURGERY PARTNERS FROM AETNA Source text for Eikon: Further company coverage:
SGRY

17
Nobilis Health Corp. Will More Than Double If It Meets Guidance

2018-03-12 seekingalpha
It trades for only 5 times the 2018 earnings guidance which benefits from two months already completed.
NHC SGRY DR HLTH DR.DB.A MFCSF

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 86881A100